Universal reference book for medicines
Name of the drug: HONDROITIN-AKOS (CHONDROITINE-AKOS)

Active ingredient: chondroitin sulfate sodium

Type: A drug regulating the metabolism in cartilaginous tissue

Manufacturer: SYNTHESIS (Russia)
Composition, form of production and packaging
Capsules
hard gelatinous, size 1, with a blue lid and a blue casing;
the contents of the capsules are white or white powder with a slightly yellowish tint of color.
1 caps.

chondroitin sodium sulfate 250 mg

Excipients: lactose, calcium stearate.

The composition of the capsule: titanium dioxide, dye azorubin, dye crimson (Ponso 4R), blue dye patented (patent blue V), dye diamond black (brilliant black BN), methyl parahydroxybenzoate (propylhydroxybenzoate), acetic acid, gelatin.

10 pieces.
- packings cellular planimetric (2) - packs cardboard.
10 pieces.
- packings cellular planimetric (5) - packs cardboard.
10 pieces.
- packings cellular planimetric (6) - packs cardboard.
INSTRUCTION FOR THE SPECIALIST.

Description of the drug approved by the manufacturer for the printed edition of 2010.

PHARMACHOLOGIC EFFECT

Stimulator of cartilage regeneration (chondroprotector).
High molecular weight mucopolysaccharide, obtained from cartilage of the trachea of ​​cattle. It affects the metabolic processes in hyaline and fibrous cartilage, reduces degenerative changes in the cartilaginous tissue of the joints, stimulates the biosynthesis of glycosaminoglycans. Promotes the regeneration of the cartilaginous surfaces of the joints and the joint bag, increases the production of intra-articular fluid. Slows the resorption of bone tissue and reduces calcium loss, accelerates the recovery of bone tissue.
When treatment with the drug decreases soreness and improves the mobility of the affected joints.
The therapeutic effect persists for a long time after the end of the course of treatment.
PHARMACOKINETICS

Suction and distribution

After taking the drug inside more than 70% of chondroitin sulfate is absorbed from the digestive tract.

After a single oral intake of the mediotherapeutic dose, Cmax in the blood plasma is reached after 3-4 hours, in synovial fluid after 4-5 hours. Bioavailability is 13%.

Chondroitin sulfate accumulates in the synovial fluid.

Excretion

It is excreted by the kidneys.

INDICATIONS

Degenerative diseases of the joints and spine:

- osteoarthrosis;

- osteocondritis of the spine.

DOSING MODE

The drug is taken orally, during or after a meal, drinking at least 1/2 cup of water.

Adults and adolescents aged 15 years and older are prescribed in a dose of 1 g / day - 2 capsules 2 times / day.
The recommended duration of the initial course of treatment is 6 months. The period of action of the drug after its cancellation is 3-5 months, depending on the location and stage of the disease. The doctor sets the duration of repeated courses of treatment individually.
SIDE EFFECT

From the digestive system: rarely -
nausea, vomiting.
Allergic reactions: rarely - hives, cutaneous erythema, skin itching.

CONTRAINDICATIONS

- children's age till 15 years;

- hypersensitivity to the components of the drug;

With caution should be used in patients with bleeding and a tendency to bleeding, with thrombophlebitis.

PREGNANCY AND LACTATION

It is not recommended to prescribe the drug during pregnancy and lactation (breastfeeding) because there is a lack of sufficient clinical data.

APPLICATION FOR CHILDREN

Contraindicated in children under 15 years of age due to the lack of accurate data on the effectiveness and safety of the drug in this category of patients.

SPECIAL INSTRUCTIONS

Contraindicated in children under 15 years of age due to the lack of accurate data on the effectiveness and safety of the drug in this category of patients.

OVERDOSE

Symptoms: rarely - nausea, vomiting, diarrhea;
with prolonged admission in excessively high doses (more than 3 g / day), hemorrhagic eruptions are possible.
Treatment: symptomatic therapy.

DRUG INTERACTION

With the simultaneous use of the drug Chondroitin-AKOS with other drugs, it is possible to increase the effect of indirect anticoagulants, antiplatelet agents, fibrinolytic agents.

TERMS OF RELEASE FROM PHARMACY

The drug is released by prescription.

TERMS AND CONDITIONS OF STORAGE

The drug should be stored out of reach of children, dry, protected from light at a temperature of no higher than 20 ° C.
Shelf life - 3 years.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Rambler's Top100
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!